摘要
目的:探讨晚期肿瘤患者血浆D-二聚体水平及低分子肝素钠的干预治疗价值。方法:采用胶乳凝集法测定晚期肿瘤患者与健康志愿者的血浆D-二聚体。对血浆D-二聚体水平高于正常的60例晚期肿瘤患者,用低分子肝素钠干预治疗1周以上,观察患者血浆D-二聚体水平的变化,患者血浆D-二聚体水平的变化与疗效和预后的关系。结果:晚期肿瘤患者血浆D-二聚体水平较健康对照组显著升高(P<0.001),不同病期与部位的肿瘤血浆D-二聚体水平有统计学差异,重症患者抗凝治疗后血浆D-二聚体水平显著下降。患者生存质量明显提高。血浆D-二聚体水平过高的患者预后差(P<0.05)。结论:低分子肝素钠抗凝治疗能防治晚期肿瘤患者的血栓栓塞性并发症,改善患者生存质量,临床获益明显。
Objective：To explore the levels of plasma D - dimer in advanced malignant patients and the intervention therapy value of low molecular weight heparin sodium. Methods：Latex agglutination test was used to detect the levels of plasma D - dimer in advanced malignant patients and healthy volunteers. Low molecular weight heparin sodium 5000IU/ d was given to sixty advanced malignant patients with high levels of plasma D - dimer by ivdrip more than 1 weeks,observed the value and change of plasma D - dimer levels,their relationship between effectiveness and prognosis of the patients. Results：The levels of plasma D - dimer in the advanced malignant patients were significantly higher than the healthy control group（P 〈0. 001）,different severity and site of the advanced malignancies showed anticoagulant therapy more than 2 weeks. The quality of life（ QOL）of the patients was improved simultaneously. high D - dimer levels in patients with poor prognosis（ P 〈 0. 05）. Conclusion：Low molecular weight heparin sodium can prevent and treat thromboembolic complications of the advanced malignancies and improve their QOL.
出处
《现代肿瘤医学》
CAS
2014年第10期2433-2436,共4页
Journal of Modern Oncology
基金
湘潭市医学会课题(编号:YXH2011008)
关键词
低分子肝素钠
D-二聚体
晚期肿瘤
治疗
预后
low molecular weight heparin sodium
D-dimer
advanced malignancies
treatment
prognosis
